Stice News

Tracey Worthington Stice and Steven Stice inside Aruna Bio.

Georgia Bio honors five

Five University of Georgia-affiliated companies and programs will be recognized with awards from Georgia Bio, the association for Georgia’s life sciences industry...Aruna Bio, a biotechnology company, received a Deal of the Year Award for raising $13 million to advance a new class of biologics targeting central nervous system disorders. Aruna Bio’s neural exosome research is headed by GRA Eminent Scholar Steven Stice.   LEARN MORE 

FDA clears IND for Aruna Bio: More on clinical trials

Rebuilding the Brain

"We’re working on very complex problems, and complex problems require a diverse set of expertise to solve.” —Steven Stice  (READ full story)

Passion led us here

Engineered by nature, and so tiny, they could fit on a single strand of hair, exosomes are powerful mediators of long-distance communication that can also deliver cargo to change the behavior of tumor and neighboring cells. For decades, scientist thought that all exosomes did was get rid of cell waste.  Today, analysts believe that the exosome technology market could reach $2.9 billion by 2030.

An early believer in the power of exosomes, Stice's UGA research lab and startup company; Aruna Bio, has been dedicated almost exclusively to the development of a proprietary exosome technology for the treatment of brain injury (namely stroke and TBI) and associated neurodegenerative disorders such as Alzheimer’s and ALS. The UGA patented treatment called AB126™ has the potential to be the first targeted therapy to reduce brain damage.

Stice's research has emerged from translating fundamental pre-clinical animal models into a pre-clinical human therapeutic. Aruna Bio is now on track to submit an Investigational New Drug with the FDA and initiate stroke patient clinical trials fall-2023. We expect this treatment to change the life of many Americans, especially in the “stroke belt” of the Southeast, where someone dies of a stroke every 40 seconds.  Stice was honored to receive the Georgia Bio Innovation Award, for what was deemed as “success in translating science into useful products that will have a positive impact on the health of individuals and the population at large.”

Stice Press

Throughout his career Stice has published and lectured internationally on regenerative medicine and his research findings have been reported in the NY Times, USA Today, Time Magazine, CNN, CBS, NBC and ABC News broadcasts.  

VIEW Current Press Stories


The collaboration between scientists, researchers and manufacturers is centered on discovering lifetime cures for escalating chronic diseases and bringing them to patients.
Aruna Bio is a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, with the aim to bring new hope to millions – for patients, for caregivers, for families.
Stice,, is working with Karumbaiah on a licensed technology for commercialization of the new Brain Glue, named best abstract at a meeting of the International Brain Injury Association. 
Hear from Steve Stice, CSO of Aruna Bio on the current industry and what 2023 will bring for the applications of exosomes for neurodegenerative diseases.